Business Wire

NTT

Share
NTT Expands Its Data Center Footprint By 20%

NTT Ltd.’s Global Data Centers division , a Leader in the IDC MarketScape Worldwide Data Center Colocation and Interconnection Services 2021 Vendor Assessment1 , provides a full stack of ICT services and continues to expand its global data center footprint by 20% to build a connected future that will benefit enterprise and hyperscale clients around the world.

NTT operates data centers across Europe, North America, Africa, and Asia, including a major presence in India. It delivers and operates global interconnected data centers with cross regional data center networks through key markets such as London, Singapore, Tokyo, and Virginia in North America. Its expansions in data center services provide increased data center capacity and network connectivity across all geographies, including:

  • Americas:

In 2020/21, three new data center campuses were opened in Hillsboro, OR, Santa Clara, CA, and Chicago, IL, in addition to expansion in Ashburn, VA. NTT’s 47-acre (approx. 190,000m2 ) Hillsboro campus features five data centers with 126MW of planned IT load and Subsea Connect, a trans-pacific network connectivity service that provides connectivity between Hillsboro, Oregon and Tokyo, Japan using NTT’s Pacific Crossing (PC-1) subsea cable system. The Phoenix, AZ campus will open in early 2022 and be the seventh US data center campus. NTT Phoenix PH1 will add 36MW of IT load capacity and is the first of seven planned data centers on the 240MW campus.

  • EMEA:

In the past year, NTT has opened new data center buildings in Amsterdam in the Netherlands, and Munich and Frankfurt in Germany, continuing its position as the number one data center provider in the German market. In the UK, the new flagship London 1 Data Center opened in December and, when fully operational, will increase NTT’s capacity by over 200% to support the digital backbone of the UK’s financial services, media, and gaming industries. NTT has also invested in duct and fiber to interconnect all its London data centers.

Over the next two years, NTT will increase its available IT load in EMEA by over 40% as it builds 13 new data center buildings across nine markets in six countries to deliver an added 115MW of IT load across 50,000m2 . NTT will launch its first data centers in Madrid and Johannesburg as well as adding buildings to Vienna, Zurich, London and across Germany, with expanded data center interconnections.

  • APAC:

Jakarta 3 in Indonesia will launch 15MW at Bekasi, approximately 30km from Central Jakarta, by the end of this year. By taking advantage of NTT’s strengths as a network operator, clients will be able to easily connect with IXs and ISPs. Additionally, Cyberjaya 5 in Malaysia started to provide 6.8MW and plan to expand another 6.8MW to the Cyberjaya campus. In Japan, a new data center with 21MW of IT load capacity has been built in Tokyo. In response to strong demand from its clients, NTT is considering further expansion in Bangkok (Thailand), Osaka Metropolitan area (Japan), and Southern Vietnam.

  • India:

With Mumbai 8 going live soon, the Chandivali campus, India’s first operational hyperscale data center park, will reach 85MW of IT load. Over the next 18 months, four new hyperscale data center parks will also become operational: two in Navi Mumbai and one each in Chennai and Delhi, adding approximately 133MW of IT load and 50,000m2 of floorspace. Interconnections for 10 data centers across India will also be rolled out in 2021 and submarine cable landing stations are planned in Mumbai and Chennai. This expansion will further consolidate NTT’s number one position in the Indian market.

In addition to the expansion of NTT’s global data center footprint, NTT is currently constructing a "MIST" large-capacity submarine cable connecting Singapore, Malaysia, and India (Mumbai and Chennai).

The MIST cable system will have a total length of 11,000km: a distance which is further than flying from New York, across the US and the Pacific Ocean to land in Tokyo. Construction will complete in mid-2023.

The infrastructure combination of such a significant increase in global data center capacity coupled with NTT’s status as a tier 1 global network service provider, will provide businesses with a secure platform for increasing full-stack ICT service needs.

Global Data Center Interconnect (GDCI) , an integrated global network fabric service that delivers a cross regional data center network and private secure connection to major cloud service providers with a single physical port supporting multiple virtual network services, increases this capability to provide a high speed interconnected digital backbone across its global markets. The increased submarine cable system will also help to provide cross-regional data center interconnections.

Masaaki Moribayashi, President and Board Director for NTT Ltd. said, “The pandemic has dramatically changed our way of life. People’s quality of life now fundamentally depends on this infrastructure. In the next 18 months, NTT plans to increase data center operations by 20% to a total of over 600,000m2 (approx. 6.5M ft2 ) of floorspace in over 20 countries and regions. In addition, NTT will globally expand approximately 30 connection points of GDCI service in our data centers to optimize the enterprise hybrid cloud environment over NTT’s data centers and network services. NTT has already started construction to add 300MW of IT load to its portfolio. With the completion of new data centers, expanded campuses and high capacity networks such as the MIST submarine cable, we are building a connected future that will benefit NTT's clients around the world.”

To contact us about your project and to see the full extent of NTT’s Global Data Center footprint, services and builds visit https://datacenter.hello.global.ntt

1 IDC MarketScape: Worldwide Datacenter Colocation and Interconnection Services 2021

-ENDS-

About the Global Data Centers division of NTT Ltd.

Global Data Centers is a division of NTT Ltd. Our global platform is one of the largest in the world. NTT is recognized as a Leader by IDC in the Worldwide Colocation and Interconnection Services MarketScape, spanning more than 20 countries and regions including North America, Europe, Africa, India and APAC. As a neutral operator, we offer access to multiple cloud providers, a large variety of Internet Exchanges and telecommunication network providers including our own IPv6 compliant, tier-one global IP network. Our clients benefit from tailored infrastructure and experience consistent best practices in design and operations across all of our reliable, scalable and customizable data centers.

Visit us at our new website datacenter.hello.global.ntt .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye